Companies: PRM   

As an ex-stockbroker, Christopher Pearce, boss of AIM-listed diagnostic hopeful Proteome Sciences, is more philosophical than many company chiefs would be about the recent collapse of Proteome's share price from 240p to 114p. Professing confidence about commercialising the company's 'platform technology' for distinguishing between certain cancer types and in the field of Alzheimer's Disease, he blames the fall on 'leveraged players, who are causing turmoil for a lot of people'.

Pearce, who says he has heard rumours of 'a big short position in the stock', hopes to confound the bears by showing that Proteome has moved from burning cash to generating it. With revenues and royalties in prospect this year and next, 'we are totally on time on our targets'.

In case the market still does not get the message, Pearce has appointed Dresdner Kleinwort Wasserstein as joint nominated adviser and broker with Evolution Beeson Gregory. 'They are strong in life sciences and making a big pitch for mid caps,' he explains.

Proteome Sciences	AIM	£29.88m	22.50p	-0.50p
Click here for interactive charting
Other company articles:
GW denied again as AIM lolls			10/06/2005
Evolution Securities - 'When, rather than if, at GW Pharma'			01/03/2005
Pearce's market medicine			02/06/2004
Christopher Spink's Pick of AIM			03/02/2004
Proteome Sciences			16/07/2003